Alphamab's bispecific checkpoint antibody enters clinic in Australia, Chinese trials planned

Alphamab Oncology (Suzhou, China) started an Australian Phase I trial of KN046 to treat advanced solid tumors. Data are expected this quarter.

Alphamab also said China's National Medical Products Administration (NMPA) approved an IND for the compound, and the company plans to start a Chinese Phase Ia/Ib trial this quarter...